2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli,Sarah Temin,Timothy Aliff,Sherman Baker,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,William Pao,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TLDR
This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.Abstract:
Purpose An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Clinical Context Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Recent Data Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who receiv...read more
Citations
More filters
Journal ArticleDOI
Maintenance therapy in non-small cell lung cancer
TL;DR: New peer-reviewed publications of phase III randomized clinical trials on maintenance chemotherapy have led to a change in current practice guidelines and the use of maintenance therapy represents a new treatment option in advanced NSCLC.
Journal Article
Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer.
TL;DR: It is shown that pemetrexed in combination with low-dose cyclophosphamide may be a better treatment approach than pemberrexed monotherapy when considering second-line treatment for wild-type EGFR NSCLC.
Journal ArticleDOI
Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells.
TL;DR: Observations suggested that NDP could have higher efficacy in DDP-resistant lung cancer cells, and further studies applying more detailed analyses are warranted to elucidate the mechanism(s) behind this effect.
Journal ArticleDOI
Development and validation of a tool for evaluating core competencies in nursing cancer patients on chemotherapy
Sung Hae Kim,Jae Hyun Park +1 more
TL;DR: The results of this study can be used for training and evaluation of core competencies for nursing cancer patients, and for standardizing nursing practices associated with chemo.
Journal ArticleDOI
Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.
TL;DR: Mesenchymal stromal cells are a new promising tool in oncology and—although not yet utilized in the clinical practice, the authors think they will represent another main tool for cancer therapy and will probably play a leading role in the field of nanovectors and molecular medicine.
References
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H. Schiller,David P. Harrington,Chandra P. Belani,Corey J. Langer,Alan B. Sandler,James E. Krook,Junming Zhu,David H. Johnson +7 more
TL;DR: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
J Oan H. S Chiller,D Avid H Arrington,C Handra P. B Elani,C Orey L Anger,A Lan S Andler,J Ames K Rook,J Unming Z Hu,D Avid H. J Ohnson +7 more
TL;DR: The response rate for all 1155 eligible pa-tients was 19 percent, with a median survival of 79 months (95 percent confidence interval, 73 to 85), a1-year survival rate of 33 percent, and a 2-year surviv-al rate of 11 percent.
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Peter Goldstraw,John Crowley,Kari Chansky,Dorothy J. Giroux,Patti A. Groome,Ramón Rami-Porta,Pieter E. Postmus,Valerie W. Rusch,Leslie H. Sobin +8 more
TL;DR: Suggestions include additional cutoffs for tumor size, with tumors >7 cm moving from T2 to T3; reassigning the category given to additional pulmonary nodules in some locations; and reclassifying pleural effusion as an M descriptor.
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Related Papers (5)
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang Yao Tsao,Miklos Pless,Thomas Müller,Hong-Liang Lim,Christopher Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more